• Reported GAAP EPS of -$0.52 down -15.56% YoY • Reported revenue of $5.14M up 70.46% YoY
Bullish
Vivos Therapeutics Inc achieved 70% revenue growth to $5.1M and expanded gross margin to 60% in Q1 2026, driven by its new medical provider-focused model. The company also successfully raised $6.1M in financing.
Bearish
Vivos Therapeutics Inc faces substantial doubt about its going concern status due to widening losses and insufficient cash. Nasdaq non-compliance and operational challenges with the SCN acquisition and clinical trial further pressure Vivos Therapeutics Inc.